SCLC: promising results with second-line lurbinectedin

  • Lancet Oncol

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lurbinectedin offers a promising overall response rate (ORR), with few serious treatment-related adverse events (AEs), as second-line therapy in patients with SCLC, who currently have few treatment options.

Why this matters

  • A randomized phase 3 trial of second-line lurbinectedin plus doxorubicin therapy for SCLC is currently underway.

Study design

  • Multicenter, international, phase 2 trial.
  • 105 patients with SCLC who failed first-line platinum-based chemotherapy received lurbinectedin.
  • Median follow-up, 17.1 months.
  • Funding: Pharma Mar.

Key results

  • Chemotherapy-free interval was
  • Overall ORR was 35.2%, and median duration of response was 5.3 months.
  • Partial response was reported in 35% of patients, and was higher in patients with a chemotherapy-free interval of ≥90 days (45% vs 22%).
  • Stable disease was reported in 33% of patients, and was higher in those with a chemotherapy-free interval of ≥90 days (37% vs 29%).
  • Progressive disease was reported in 27% of patients, and was higher in those with a chemotherapy-free interval of
  • Median OS (9.3 months) and PFS (3.5 months) were longer in patients with a chemotherapy-free interval of ≥90 days.
  • 10% reported serious treatment-related AEs.

Limitations

  • Single-group, open-label trial.